Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Trigeminal nerve Stories

2013-07-29 08:25:55

External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy LOS ANGELES, July 29, 2013 /PRNewswire/ -- NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device Exemption (IDE) application to commence a Phase III pivotal trial of the Monarch(TM) eTNS(TM) System for treatment of drug resistant epilepsy. The Company is planning to conduct a multi-center trial at leading medical institutions in...

2013-06-06 08:28:58

Comprehensive Clinical and Product Information for Patients and Physicians in the European Union and Canada LOS ANGELES, June 6, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced the launch of www.monarch-etns.com, its dedicated website for the Monarch(TM) eTNS(TM) System. The new site provides a comprehensive resource for those in the European Union and Canada who are considering use of the non-invasive Monarch system to treat their...

2013-05-22 23:24:15

Meniere's Disease & Trigeminal Neuralgia Breakthrough; a Story of Survival! Learn about important traditional & complementary alternatives to one-sided neurological problems. Grand Rapids, MI (PRWEB) May 22, 2013 The featured speaker at this year´s Meniere's Disease Research Institute's Workshop is Dr. Michael T. Burcon, world's leading expert on Meniere's disease (MD). Burcon has proven a correlation between MD and whiplash (caused by a vehicular accident or a fall on the...

2013-05-02 08:35:12

Non-Invasive Neurostimulation System, Well-Received in Europe, Now Available in Canada for Adults and Children 9 years and older LOS ANGELES, May 2, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its Monarch(TM) eTNS(TM) (external trigeminal nerve stimulation) System from Health Canada.  The license covers the use of the Monarch eTNS System for treatment of drug-resistant...

2013-04-18 04:21:34

To Be Presented May 20, 2013 At American Psychiatric Association Annual Meeting in San Francisco LOS ANGELES, April 18, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that the results of the first-ever pediatric clinical trial of external Trigeminal Nerve stimulation (eTNS(TM)) for the treatment of attention-deficit hyperactivity disorder (ADHD) will be presented at the American Psychiatric Association annual meeting in San...

2013-04-16 23:00:13

Physician Education Event Highlights New Treatment Options for Trigeminal Nerve Repair. Alachua, FL (PRWEB) April 16, 2013 AxoGen, Inc. (OTCBB: AXGN) a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it is sponsoring a panel discussion on nerve repair and protection at the American College of Oral and Maxillofacial Surgeons (ACOMS) 2013 Annual Scientific...

Crocodiles’ Sensitive Faces Help Understand Ancestors
2013-04-05 11:23:20

Watch the video "Measuring a Crocodile's Smile" redOrbit Staff & Wire Reports - Your Universe Online The ultra-sensitive nerves in the faces of crocodilians could help biologists understand how both modern and ancient animals interact with their environment, according to a new study in this month´s edition of The Anatomical Record. These nerves are so sensitive that they can detect changes in a pond when a single droplet of water hits the surface several feet away....

2013-03-25 04:22:08

UCLA Case Study Results To Be Presented At Major International Status Epilepticus Conference In Salzburg, Austria LOS ANGELES, March 25, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive Monarch(TM) eTNS(TM) System for the adjunctive treatment of epilepsy and depression, at the 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures to be held in Salzburg, Austria...

2013-02-11 04:20:41

LOS ANGELES, Feb. 11, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that Christopher DeGiorgio, M.D., Vice President of Neurology at NeuroSigma and Professor of Neurology at the University of California, Los Angeles (UCLA), and Colin Kealey, M.D., Manager of Business Development at NeuroSigma, will present in London, an overview of external trigeminal nerve stimulation (eTNS(TM)) for the treatment of epilepsy and depression at The Royal...

2013-02-04 08:25:15

LOS ANGELES, Feb. 4, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced it received a Notice of Award, for a Fast Track Small Business Innovation Research (SBIR) grant, from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Phase I of the project is budgeted in the amount of $600,000, with $3 Million budgeted for Phase II, subject to the availability of funds and satisfactory progress...